Founding Partner
Partner
|
|
|
|
|
|
© 2018 ISAR Bioscience GmbH | Semmelweisstr. 5, D-82152 Planegg | Contact Us
Scientific Director Neurodegeneration & Genome Engineering
Prof. Dr. Dominik Paquet serves as Scientific Director Neurodegeneration & Genome Engineering. He is Professor of Neurobiology at the Institute of Stroke and Dementia Research (ISD) of Ludwig-Maximilians-University Munich and member of the Munich Cluster of Systems Neurology (SyNergy). Dr. Paquet leads a research lab at ISD, which focusses on developing iPSC-based models or Neurodegenerative and Neurovascular disorders. Previously, he worked with Marc Tessier-Lavigne at The Rockefeller University in New York, USA, where he published seminal studies on CRISPR/Cas genome engineering and disease modeling of Alzheimer’s and related dementias in iPSCs. Dr. Paquet holds a degree in Biology from University of Tübingen and Sheffield, UK and a doctorate in Biochemistry and Pharmacology from LMU Munich. He received several research awards including the International Leda-Hanin- and Verum-Awards for AD research, the Young Investigator Award of the Universität Bayern, and fellowships from the Elite Network of Bavaria, the German Academy of Sciences Leopoldina and The New York Stem Cell Foundation. At ISAR Dr. Paquet leads the development and translational application of iPSC-based models of neurodegenerative diseases.
Program Director Neurodegeneration
Dr. Gernot Kleinberger serves as Program Director Neurodegeneration. He received his Diploma in Biotechnology from the IMC University of Applied Sciences in Krems, Austria and obtained a Ph.D. in Biomedical Research from the University of Antwerp, Belgium, where he established cellular and animal models to study the role of progranulin deficiency in neurodegeneration. Prior to joining ISAR, Dr. Kleinberger successfully established cellular and animal models to investigate microglia targets such as TREM2, which are associated with several neurodegenerative diseases including Alzheimer’s disease and published seminal papers with Professor Christian Haass at the German Center for Neurodegenerative Disorders (DZNE) in Munich. He will build on his track record in modeling mechanisms of neurodegenerative processes to establish the next generation of cell-based neurodegenerative disease models that will advance development of therapeutics to treat neurodegeneration.
Member of the Supervisory Board
Heinrich Hofmann serves as Member of the Supervisory Board. Heinrich Hofmann is Major of Planegg, Germany.
Member of the Supervisory Board
Dr. Christian A. Stein serves as Member of the Supervisory Board. Christian Stein is Managing Director of Ascenion GmbH in Munich, Germany.
Member of the Supervisory Board
Dr. Jörn Erselius serves as Member of the Supervisory Board. Jörn Erselius is Managing Director at Max-Planck-Innovation in Munich, Germany.
Chairman of the Supervisory Board
Dr. Manfred Wolter serves as Chairman of the Supervisory Board. Ministerialdirigent Dr. Manfred Wolter is Head of the Department “Innovation, Research, Technology, Digitalisation” at the Bavarian Ministry of Economic Affairs, Energy and Technology.
Deputy Director of the Board, StemCellRegMed Foundation
Johanna Boeck-Heuwinkel serves as Deputy Director of the StemCellRegMed Foundation Board. She is Attorney of Law & Senior Consultant. Her experience comprises realization of strategic academic-corporate partnerships in the public sector and 15 years support of scientist entrepreneurs during the foundation phase of technology start-ups in the metropolitan areas of Düsseldorf, Hamburg and Munich.
Director of the Board, StemCellRegMed Foundation
Prof. Dr. Horst Domdey serves as Director of the StemCellRegMed Foundation Board. Horst Domdey is Managing Director of BioM – Biotechnology Cluster Management for Munich & Bavaria.
Director Board of Trustees, StemCellRegMed Foundation
Prof. Dr. Hans R. Schöler is founding team member and serves as Director of the Board of Trustees of the StemCellRegMed Foundation. Hans Schöler is Director of the Department of Cell and Developmental Biology at the Max-Planck-Institute for Molecular Biomedicine in Münster, Germany.
Dr. Schöler studied Biology at Heidelberg University and received his PhD at the Center for Molecular Biology Heidelberg (ZMBH). He was Research Group Leader with Boehringer Mannheim and Scientific Fellow at the Max-Planck-Institute for Biophysical Chemistry in Göttingen before he headed a research group at the European Molecular Biology Laboratory (EMBL) in Heidelberg. Dr. Schöler received his Venia Legendi in Molecular Biology at the Biological Faculty of Heidelberg University and was then appointed Professor, the Marion Dilley and David George Jones Chair for Reproductive Medicine and Director of the Center for Animal Transgenesis and Germ Cell Research (CATGCR) at the University of Pennsylvania (PENN), School of Veterinary Medicine, Department of Animal Biology in Philadelphia, USA. He still serves at PENN as an Adjunct Professor of Biochemistry. He is also a Professor at the Medical Faculty of the Westphalian Wilhelms University in Münster and Adjunct Professor at the Hanover Medical School (MHH) as well as a Distinguished Professor at Konkuk University, Seoul, South Korea. In 2010 the Ulsan National Institute of Science and Technology (UNIST) opened the Hans Schöler Stem Cell Research Center (HSSCRC) in Ulsan, South Korea.
Chief Scientific Advisor of ISAR Bioscience
Prof. Dr. Dr. h.c. Christian Haass serves as Chief Scientific Advisor. He is Head of the Department of Metabolic Biochemistry at the Biomedical Center of Ludwig-Maximilians-University Munich and Speaker of the German Center for Neurodegenerative Disorders (DZNE) and of the Munich Cluster of Systems Neurology (SyNergy).
Dr. Haass graduated in Molecular Biology at the University of Heidelberg, Germany. He was a postdoc and assistant professor of Neurology at Harvard Medical School in the institute of Dr. Dennis Selkoe. He received a number of prestigious awards, among them the Gottfried Wilhelm Leibniz-Award of the Deutsche Forschungsgemeinschaft, the Potamkin Award of the American Academy of Neurology, an ERC advanced grant, and most recently the Brain prize.
CTO of ISAR Bioscience
Dr. Andreas Hochheimer is founding team member and serves as Chief Technology Officer and Head of R&D & Translational Science. He served previously at AMGEN heading HTS drug discovery of pharmaceutical targets in neurodegenerative, inflammatory and metabolic disorders as well as oncology. He is University Lecturer in Biochemistry/Molecular Cell Biology and successfully established translational R&D programs as well as corporate-academic partnerships. Prior to AMGEN, he led the Human-Taste-Cell discovery research and business development program at BRAIN AG to implement human taste cells for taste modulator screening and to investigate human taste cell physiology. Dr. Hochheimer received a degree in Biology and Ph.D. in Microbiology from Philipps-University Marburg. He was Professor in Biochemistry at Ludwig-Maximilians-University Munich and further received Venia Legendi and had faculty appointments at Technical University Darmstadt and University Regensburg.
CEO of ISAR Bioscience
Dr. Ulrich C. Gerth is Founding Director and serves as Chief Executive Officer. He is a Science Manager and has a track record as Technology Transfer and Innovation Manager with strategic and operational responsibilities. Previously he served as Business Analyst at the global consulting firm Ernst & Young, as a Financial Analyst for equity markets and corporate finance at HypoVereinsbank, Senior Analyst at a Federal Government Agency, New Products Planning Manager at Wyeth Pharma, and Deputy Head of Business Development Med- and Biotech at the fonds management service provider IPB AG for Deutsche Bank AG. Dr. Gerth was designated Managing Director of CARE (Center for Advanced Regenerative Engineering) to build a translational research reference center for applied stem cell research, which he successfully launched as ISAR Bioscience in 2018. He received his DPhil in molecular immunology from Oxford University at the MRC Weatherall Institute of Molecular Medicine.